Management of donor‐site complications after breast reconstruction with the transverse musculocutaneous gracilis flap: Proposal of a treatment algorithm

Abstract

AbstractBackgroundThe transverse myocutaneous gracilis (TMG) flap is a popular choice for autologous breast reconstruction due to its consistent anatomy and reliability, especially for slim patients. While the incidence of donor‐site morbidity is comparable with other free flaps, there is no literature about the management of donor‐site complications available. Our study aims to provide an overview of encountered complications, associated risk factors and their management using a standardized algorithmic approach.MethodsA retrospective review of all patients receiving breast reconstruction with a TMG flap at our institution between September 2010 and May 2021 was performed. Demographic data (age, BMI), comorbidities (diabetes, smoking), complication rates (major, minor) and treatment were evaluated. Medical records were screened for reasons and timing of performed reconstructions. Adapted from the Clavien‐Dindo classification system, severity of complication was categorized as either class I–II minor or class IIIa–IIIb major. Data on follow‐up procedures was collected. A treatment algorithm for the management of commonly occurring donor‐site complications was created, based on our long‐running institutional experience.ResultsTwo‐hundred and twenty‐five patients (288 flaps) were included in our retrospective analysis. There were 43 (14.9%) minor and 4 (2.7%) major donor‐site complications overall. Minor complications included superficial wound breakdown (26/9%), infection (10 cases, 3.5%) and hematoseroma (7 cases, 2.4%). Hematoseroma (2 cases, 0.7%) and severe wound breakdown (2 cases, 0.7%) needing revision surgery were the most common major complications. Patients with lower BMI (mean 22.9 kg/m2 vs. 24.0 kg/m2; p = .047) and active tobacco use (14.1% vs. 6.3%; p = .046; Relative risk = 1.71 95% CI 1.02–2.88) had a higher occurrence of donor‐site complications. Age and operating time were not associated with higher complication rates. Four patients (1.4%) received donor‐site refinement surgery.ConclusionThe TMG flap provides a reliable and safe alternative for breast reconstruction and most donor‐site complications can be managed conservatively. Our proposed treatment algorithm aids with decision making in the management of donor‐site complications.